Risk assessment and QbD based optimization of an EPROSARTAN (cas 133040-01-4) mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment

Add time:09/08/2019    Source:sciencedirect.com

Quality by design (QbD) principles were implemented to understand the product and process variables of sonoprecipitation technique, for preparation of EPROSARTAN (cas 133040-01-4) mesylate (EM) nanosuspension. Quality risk management approach was utilized to identify and assess high-risk attributes affecting critical quality attributes (CQA’s), prioritizing the number of experiments. The effect of critical material attributes (CMA’s) and critical process parameters (CPP’s) (soluplus concentration, drug concentration ultrasonication amplitude) on z-average particle size and PDI were investigated using a central composite face-centered design (CCF). Further, design space with criteria set of CMA’s and CPP’s was established to offer assurance of quality. The optimal formulation, identified using numerical optimization method, was further lyophilized and evaluated for redispersibility, solubility saturation, dissolution kinetic and in-vitro dissolution behavior. The EM nanoparticles were in an amorphous state as confirmed by differential scanning calorimetry (DSC) and X-ray diffraction (XRD) studies. The stability study conducted for a span of 6 months attests physical and chemical stability of EM dry nanosuspension in an amorphous state when stored at 4 °C. The enhanced solubility and in-vitro dissolution of EM nanosuspension may be attributed to the reduced particle size and alteration of the physical state from a crystalline to an amorphous state. Further, the optimized formulation was subjected to in-vitro and ex-vivo transport study using parallel artificial membrane permeability assay (PAMPA) and rat everted gut sac model respectively. The transport studies revealed successful permeation enhancement of EM nanoparticle when compared with EM API and physical mixture (PM). The absolute bioavailability of EM API was 7.1% and improved to 39.9% for EM nanosuspension, suggesting that nanoformulation had overcome solubility and permeability limited bioavailability which was observed with EM API.

We also recommend Trading Suppliers and Manufacturers of EPROSARTAN (cas 133040-01-4). Pls Click Website Link as below: cas 133040-01-4 suppliers

Prev:Original articleEffectiveness of EPROSARTAN (cas 133040-01-4) in diabetic hypertensive patients
Next:Original ArticleDetermination and characterization of process impurities for EPROSARTAN (cas 133040-01-4) mesylate)